Cargando…
HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells
Poly(ADP‐ribose) polymerase 1 inhibitors alone or in combination with DNA damaging agents are promising clinical drugs in the treatment of cancer. However, there is a need to understand the molecular mechanisms of resistance to PARP1 inhibitors. Expression of HMGA2 in cancer is associated with poor...
Autores principales: | Hombach‐Klonisch, Sabine, Kalantari, Forouh, Medapati, Manoj Reddy, Natarajan, Suchitra, Krishnan, Sai Nivedita, Kumar‐Kanojia, Aditya, Thanasupawat, Thatchawan, Begum, Farhana, Xu, Fred Y., Hatch, Grant M., Los, Marek, Klonisch, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360374/ https://www.ncbi.nlm.nih.gov/pubmed/30289618 http://dx.doi.org/10.1002/1878-0261.12390 |
Ejemplares similares
-
Mechanisms of Therapeutic Resistance in Cancer (Stem) Cells with Emphasis on Thyroid Cancer Cells
por: Hombach-Klonisch, Sabine, et al.
Publicado: (2014) -
Nuclear High Mobility Group A2 (HMGA2) Interactome Revealed by Biotin Proximity Labeling
por: Gaudreau-Lapierre, Antoine, et al.
Publicado: (2023) -
Novel CTRP8‐RXFP1‐JAK3‐STAT3 axis promotes Cdc42‐dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells
por: Glogowska, Aleksandra, et al.
Publicado: (2021) -
RXFP1 is Targeted by Complement C1q Tumor Necrosis Factor-Related Factor 8 in Brain Cancer
por: Thanasupawat, Thatchawan, et al.
Publicado: (2015) -
Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes
por: Thanasupawat, Thatchawan, et al.
Publicado: (2021)